A pharmaceutical formulation comprising at least one negative allosteric modulator of the mGluR5 receptor and at least one pharmaceutically acceptable excipient in the form of an enteric tablet, enteric capsule or multiple unit dosage form has improved activity for the treatment of Parkinson’s disease.一種於腸溶型錠劑、腸溶型膠囊或多單位劑型之形式的醫藥調合物具有治療帕金森氏症之改良活性,該醫藥調合物包含至少一種mGluR5受體之負向異位調節劑及至少一種醫藥上可接受的賦形劑。